Eidos Therapeutics, Inc. Insider Trading for January 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Eidos Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Eidos Therapeutics, Inc. for January 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Option Exercise | D | 13.20 | 70,000 | 924,000 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Sell | U | 0.00 | 380,467 | 0 | 0 | 380.5 K to 0 (-100.00 %) |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Fox Jonathan C | See Remarks | Gift | G | 0.00 | 500 | 0 | 380,467 | 381 K to 380.5 K (-0.13 %) |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Rohlen Douglas | Director | Option Exercise | D | 0.00 | 4,526 | 0 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Rohlen Douglas | Director | Option Exercise | D | 41.42 | 21,447 | 888,335 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | D | 7.24 | 24,350 | 176,294 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | D | 13.20 | 53,157 | 701,672 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Option Exercise | D | 17.00 | 9,469 | 160,973 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Turtle Cameron | Chief Business Offi ... | Sell | U | 0.00 | 50,699 | 0 | 0 | 50.7 K to 0 (-100.00 %) |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | D | 20.34 | 43,056 | 875,759 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | D | 30.87 | 21,528 | 664,569 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Satvat Ali J. | Director | Option Exercise | D | 48.51 | 21,528 | 1,044,323 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Lis William | Director | Option Exercise | D | 13.67 | 43,056 | 588,576 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Lis William | Director | Option Exercise | D | 30.87 | 21,528 | 664,569 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Lis William | Director | Option Exercise | D | 48.51 | 21,528 | 1,044,323 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Hooper Suzanne Sawochka | Director | Option Exercise | D | 0.00 | 4,526 | 0 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Hooper Suzanne Sawochka | Director | Option Exercise | D | 41.42 | 21,447 | 888,335 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Option Exercise | D | 13.20 | 60,000 | 792,000 | 0 | |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | U | 0.00 | 303,525 | 0 | 0 | 303.5 K to 0 (-100.00 %) |
| Jan 28 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Gift | G | 0.00 | 3,000 | 0 | 303,525 | 306.5 K to 303.5 K (-0.98 %) |
| Jan 26 2021 | EIDX | Eidos Therapeutics ... | BridgeBio Pharma, Inc. | 10% Owner | Buy | P | 0.00 | 14,428,836 | 0 | 1,000 | -14,427,836 to 1,000 (-100.01 %) |
| Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 126.39 | 300 | 37,917 | 306,525 | 306.8 K to 306.5 K (-0.10 %) |
| Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 125.35 | 2,000 | 250,700 | 306,825 | 308.8 K to 306.8 K (-0.65 %) |
| Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 124.72 | 4,934 | 615,362 | 308,825 | 313.8 K to 308.8 K (-1.57 %) |
| Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 123.48 | 1,498 | 184,971 | 313,759 | 315.3 K to 313.8 K (-0.48 %) |
| Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 122.27 | 572 | 69,937 | 315,257 | 315.8 K to 315.3 K (-0.18 %) |
| Jan 15 2021 | EIDX | Eidos Therapeutics ... | Sinha Uma | Chief Scientific Of ... | Sell | S | 121.11 | 696 | 84,292 | 315,829 | 316.5 K to 315.8 K (-0.22 %) |
| Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 1,747 | 12,648 | 24,350 | |
| Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Option Exercise | M | 7.24 | 1,500 | 10,860 | 26,097 | |
| Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 125.45 | 1,747 | 219,152 | 0 | 1.7 K to 0 (-100.00 %) |
| Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 1,747 | 12,648 | 1,747 | 0 to 1.7 K |
| Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Sell | S | 125.61 | 1,500 | 188,408 | 0 | 1.5 K to 0 (-100.00 %) |
| Jan 13 2021 | EIDX | Eidos Therapeutics ... | Valle Franco | Senior Vice Preside ... | Buy | M | 7.24 | 1,500 | 10,860 | 1,500 | 0 to 1.5 K |